Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daxdilimab in moderate-to-severe primary Discoid Lupus Erythematosus
NCT05591222Phase 2Terminated
- Sponsor
- Amgen
- Start
- Dec 2022
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of daxdilimab in discoid lupus erythematosus (DLE), sponsored by Amgen. Started Dec 2022; status: terminated.
02
Drugs
daxdilimab
03
Conditions
discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on NCT05591222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05591222.